http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102480964-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-54
filingDate 2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26bd93251cfc5ac5a578d5849529849d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2421ef2a04c16526afa26a03fc1a0e38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e52c692bbdd2018dad0315b20e0609
publicationDate 2012-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-102480964-A
titleOfInvention Pyranylarylmethylbenzoquinazolone M1 receptor positive allosteric modulator
abstract The present invention relates to a pyranyl arylmethyl benzoquinazolinone compound of formula (I), which is a positive allosteric modulator of M1 receptors and can be effectively used in the treatment of diseases involving M1 receptors, such as Al Alzheimer's disease, schizophrenia, pain, or sleep disturbance. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the compound and the composition in treating diseases mediated by M1 receptors.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107922403-A
priorityDate 2009-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008002621-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008011032-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102292323-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465172674
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163572424

Total number of triples: 35.